-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, Shanxi Pharmaceutical Equipment Center issued a notice on the price reduction of some drugs, involving a total of 22 varieties from 19 companies, involving varieties with a unit price of more than 1,000 yuan, including doxorubicin hydrochloride liposome injection, ceti Distributing injections, etc.
, will be implemented since the release
.
According to the announcement, the price reduction is for the enterprise to apply for it voluntarily
.
It is understood that since the beginning of this year, Shanxi Pharmaceutical Equipment Center has issued several notices of price reduction
.
On July 26, the Shanxi Provincial Pharmaceutical Equipment Centralized Bidding and Purchasing Network issued the "Shanxi Province Notice on Adjusting the Online Drug Prices of 7 Enterprises including Guangdong Dongguang Pharmaceutical Co.
, Ltd.
" (Jin Yaozhao [2022] No.
97), according to the company Application, 7 companies including Guangdong Dongguang Pharmaceutical Co.
, Ltd.
and 9 drugs listed on the Internet price for adjustment
.
According to the "Catalogue of Adjustment of Enterprises' Drugs on the Internet", the price adjustment on the Internet has decreased by 10%.
The drug with a larger decrease is the Propofol Emulsion Injection of Beijing Fresenius Kabi Pharmaceutical Co.
, Ltd.
It reached 25.
57%, followed by the Vascular Rehabilitation Tablets of Shanxi Renyuantang Pharmaceutical Co.
, Ltd.
, with a decrease of 22.
69%
.
Recently, in addition to Shanxi Province, Sichuan, Heilongjiang and other places have also intensively issued notices of drug price reductions.
From the perspective of price reductions, many varieties have dropped by more than 90%
.
For example, the "Notice on Publicizing the Price Reduction of Some Drugs" issued by the Sichuan Provincial Pharmaceutical Equipment Centralized Purchasing and Pharmaceutical Price Supervision Platform recently showed that 171 batches of products from 142 pharmaceutical companies adjusted their prices.
Among them, Sandoz (China) Pharmaceutical's Voriconazole Tablets ( 200 mg) from 161,565 yuan/box to 5,385.
5 yuan/box, a drop of 97%
.
On August 8, the Heilongjiang Centralized Drug Purchasing Network announced the information on the price adjustment of enterprises' independent application in July 2022
.
According to the review, a total of 214 varieties have been reduced in price, including Zai Lab's Ripatinib, Pfizer's Palbociclib Capsules, AbbVie's Veneclax Tablets, and Boehringer Ingelheim's Belintoumumab for Injection, etc.
A variety of heavyweight varieties
.
Among them, Liuwei Dihuang Pills (film-coated pills) and other medical insurance drugs dropped by more than 90%
.
In addition to domestic pharmaceutical companies, in fact, since this year, many original research drugs have also joined the team of active price reduction
.
In June, Shandong Pharmaceutical Equipment Centralized Procurement Platform issued a notice that Roche voluntarily lowered the price of Risprolan, a rare disease drug for spinal muscular atrophy (SMA), and the online price dropped to 14,500 yuan per bottle
.
In the same month, Roche Pharmaceuticals also announced a reduction in the price of Hercelite (trastuzumab for injection), after the price adjustment, the price of 100 mg is 8,340 yuan, and the price of 160 mg is 11,951.
63 yuan
.
It is generally believed in the industry that there are continuous drug price reductions, mainly due to the normalization and intensification of the centralized and intensive procurement of drugs from the state to local governments, urging enterprises to actively adjust prices, and squeezing the space for artificially high drug prices
.
In the National Medical Insurance Bureau, it is clear that during the "14th Five-Year Plan" period, the centralized procurement of medicines and medical consumables will be increased, and centralized procurement will become the dominant mode.
Under the background of the centralized procurement scope of medical consumables, more medicines and consumables will also usher in the fate of price reduction
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
, will be implemented since the release
.
According to the announcement, the price reduction is for the enterprise to apply for it voluntarily
.
It is understood that since the beginning of this year, Shanxi Pharmaceutical Equipment Center has issued several notices of price reduction
.
On July 26, the Shanxi Provincial Pharmaceutical Equipment Centralized Bidding and Purchasing Network issued the "Shanxi Province Notice on Adjusting the Online Drug Prices of 7 Enterprises including Guangdong Dongguang Pharmaceutical Co.
, Ltd.
" (Jin Yaozhao [2022] No.
97), according to the company Application, 7 companies including Guangdong Dongguang Pharmaceutical Co.
, Ltd.
and 9 drugs listed on the Internet price for adjustment
.
According to the "Catalogue of Adjustment of Enterprises' Drugs on the Internet", the price adjustment on the Internet has decreased by 10%.
The drug with a larger decrease is the Propofol Emulsion Injection of Beijing Fresenius Kabi Pharmaceutical Co.
, Ltd.
It reached 25.
57%, followed by the Vascular Rehabilitation Tablets of Shanxi Renyuantang Pharmaceutical Co.
, Ltd.
, with a decrease of 22.
69%
.
Recently, in addition to Shanxi Province, Sichuan, Heilongjiang and other places have also intensively issued notices of drug price reductions.
From the perspective of price reductions, many varieties have dropped by more than 90%
.
For example, the "Notice on Publicizing the Price Reduction of Some Drugs" issued by the Sichuan Provincial Pharmaceutical Equipment Centralized Purchasing and Pharmaceutical Price Supervision Platform recently showed that 171 batches of products from 142 pharmaceutical companies adjusted their prices.
Among them, Sandoz (China) Pharmaceutical's Voriconazole Tablets ( 200 mg) from 161,565 yuan/box to 5,385.
5 yuan/box, a drop of 97%
.
On August 8, the Heilongjiang Centralized Drug Purchasing Network announced the information on the price adjustment of enterprises' independent application in July 2022
.
According to the review, a total of 214 varieties have been reduced in price, including Zai Lab's Ripatinib, Pfizer's Palbociclib Capsules, AbbVie's Veneclax Tablets, and Boehringer Ingelheim's Belintoumumab for Injection, etc.
A variety of heavyweight varieties
.
Among them, Liuwei Dihuang Pills (film-coated pills) and other medical insurance drugs dropped by more than 90%
.
In addition to domestic pharmaceutical companies, in fact, since this year, many original research drugs have also joined the team of active price reduction
.
In June, Shandong Pharmaceutical Equipment Centralized Procurement Platform issued a notice that Roche voluntarily lowered the price of Risprolan, a rare disease drug for spinal muscular atrophy (SMA), and the online price dropped to 14,500 yuan per bottle
.
In the same month, Roche Pharmaceuticals also announced a reduction in the price of Hercelite (trastuzumab for injection), after the price adjustment, the price of 100 mg is 8,340 yuan, and the price of 160 mg is 11,951.
63 yuan
.
It is generally believed in the industry that there are continuous drug price reductions, mainly due to the normalization and intensification of the centralized and intensive procurement of drugs from the state to local governments, urging enterprises to actively adjust prices, and squeezing the space for artificially high drug prices
.
In the National Medical Insurance Bureau, it is clear that during the "14th Five-Year Plan" period, the centralized procurement of medicines and medical consumables will be increased, and centralized procurement will become the dominant mode.
Under the background of the centralized procurement scope of medical consumables, more medicines and consumables will also usher in the fate of price reduction
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
